SITS was given a broader international role with the European Union authorities requesting that all patients treated with IV thrombolysis should be registered in SITS for a period of three years.
Registration in SITS became a condition for approval of treatment with intravenous thrombolysis in the EU.
Also, the European Medicines Agency (then EMEA, currently EMA) endorsed SITS as the registry for follow-up on thrombolysis treatment in acute ischemic stroke.